Free Trial
TSE:GUD

Knight Therapeutics (GUD) Stock Price, News & Analysis

Knight Therapeutics logo
C$6.50 +0.10 (+1.56%)
As of 08/29/2025 04:00 PM Eastern

About Knight Therapeutics Stock (TSE:GUD)

Key Stats

Today's Range
C$6.41
C$6.55
50-Day Range
C$5.75
C$6.54
52-Week Range
C$5.09
C$6.55
Volume
36,913 shs
Average Volume
66,509 shs
Market Capitalization
C$647.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$7.15
Consensus Rating
Buy

Company Overview

Knight Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

GUD MarketRank™: 

Knight Therapeutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Knight Therapeutics has received no research coverage in the past 90 days.

  • Read more about Knight Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Knight Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Knight Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.

  • Price to Book Value per Share Ratio

    Knight Therapeutics has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for GUD.
  • Dividend Yield

    Knight Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Knight Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GUD.
  • News Sentiment

    Knight Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for GUD on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.73% of the stock of Knight Therapeutics is held by institutions.

  • Read more about Knight Therapeutics' insider trading history.
Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GUD Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
Collective, Knight at 52-Week Highs on News
Sime Armoyan selling more Knight Therapeutics (GUD)
See More Headlines

GUD Stock Analysis - Frequently Asked Questions

Knight Therapeutics' stock was trading at C$5.34 at the beginning of 2025. Since then, GUD stock has increased by 21.7% and is now trading at C$6.50.

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
TSE:GUD
CIK
N/A
Fax
N/A
Employees
725
Year Founded
N/A

Price Target and Rating

High Price Target
C$7.50
Low Price Target
C$6.50
Potential Upside/Downside
+10.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
64.39
P/E Growth
-1013.5
Net Income
-C$30.73 million
Net Margins
-8.81%
Pretax Margin
N/A
Return on Equity
-4.04%
Return on Assets
0.51%

Debt

Debt-to-Equity Ratio
7.52
Current Ratio
3.36
Quick Ratio
1.79

Sales & Book Value

Annual Sales
C$384.56 million
Price / Sales
1.68
Cash Flow
C$1.69 per share
Price / Cash Flow
3.85
Book Value
C$7.65 per share
Price / Book
0.85

Miscellaneous

Outstanding Shares
99,653,000
Free Float
N/A
Market Cap
C$647.74 million
Optionable
Not Optionable
Beta
0.19
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (TSE:GUD) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners